Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.

Abstract	Long-term effects of therapeutic vaccination of human immunodeficiency virus (HIV)-1-infected subjects with HIV-1 p17/p24:Ty virus-like particles (p24-VLP) on progression to AIDS, death, a CD4 cell count <or=200 cells/mm(3) and CD4 cell count decline were studied in a multicenter cohort study of 56 individuals who participated in a phase II double-blind placebo-controlled trial with p24-VLP in 1993. Using Cox proportional hazard analysis, no difference between vaccine and placebo groups was found in progression to death (adjusted hazard rate (HR): 0.68 (95% CI: 0.05-7.83), AIDS (adjusted HR: 1.07 (95% CI: 0.21-5.36)) and a CD4 cell count <or=200 cells/mm(3) (adjusted HR: 1.00 (95% CI: 0.35-2.87)). Using linear regression with correction for multiple visits within one person, no effect of vaccination on CD4 cell count decline, adjusted for antiretroviral therapy (ART) use, was found (P=0.98). In conclusion, therapeutic vaccination with p24-VLP is not related to slower HIV-1 disease progression.
Authors	Catharina E A Lindenburg, Ineke Stolte, Miranda W Langendam, Frank Miedema, Ian G Williams, Robert Colebunders, Jonathan N Weber, Martin Fisher, Roel A Coutinho
Journal	Vaccine (Vaccine) Vol. 20 Issue 17-18 Pg. 2343-7 (May 22 2002) ISSN: 0264-410X [Print] Netherlands
PMID	12009290 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References	AIDS Vaccines Gene Products, gag HIV Antigens HIV Core Protein p24 Viral Proteins gag Gene Products, Human Immunodeficiency Virus p17 protein, Human Immunodeficiency Virus Type 1 p24-VLP vaccine
Topics	AIDS Vaccines (immunology, therapeutic use) Aged CD4 Lymphocyte Count Disease Progression Double-Blind Method Female Follow-Up Studies Gene Products, gag (immunology, therapeutic use) HIV Antigens (immunology, therapeutic use) HIV Core Protein p24 (immunology, therapeutic use) HIV Infections (immunology, physiopathology, therapy) HIV-1 (immunology) Humans Male Middle Aged Time Factors Vaccination Viral Proteins gag Gene Products, Human Immunodeficiency Virus

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!